Market Overview

Stocks Hitting 52-Week Highs

Share:
Related MDVN
US Stock Futures Up; All Eyes On Fed Decision
UPDATE: Medivation, Astellas Report Enrollment of First Patients in Advanced Prostate Cancer
Medivation Voted Three Years in a Row Among Top Workplaces in the San Francisco Bay Area (GuruFocus)
Related TEVA
Wednesday's Mid-Day Movers: Chubb, Rock Creed, RADA Win; Peabody Energy, Ballard Fall
Top Takeaways From BMO's Specialty Pharma Day
Teva, Xenon Pain Drug Fails Phase IIb Study, Xenon Slumps - Analyst Blog (Zacks)

Medivation (NASDAQ: MDVN) shares touched a new 52-week high of $86.54 after the company and Astellas reported final results from the Phase 3 PREVAIL trial of Enzalutamide. Credit Suisse lifted the price target on Medivation from $80.00 to $95.00.

Teva Pharmaceutical Industries (NYSE: TEVA) shares reached a new 52-week high of $45.60 after the company reported the FDA approval of three-times-a-week COPAXONE 40mg/mL.

CBRE Group (NYSE: CBG) shares jumped 1.54% to touch a new 52-week high of $27.06. CBRE Group is expected release its Q4 financial results on February 5, 2014.

Jones Lang LaSalle (NYSE: JLL) shares surged 5.69% to reach a new 52-week high of $112.36 after the company reported stronger-than-expected Q4 results.

Posted-In: 52-Week HighsNews Intraday Update Markets Movers

 

Related Articles (CBG + JLL)

Around the Web, We're Loving...

Get Benzinga's Newsletters